IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting now · Phase 1

Conditions studied: Locally Advanced Solid Tumor

In brief

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Key facts

Study ID

NCT06349408

Run by

Innovent Biologics (Suzhou) Co. Ltd.

People needed

250

Starts

2025-01-10

Expected to finish

2027-12-31

Last updated by the study team

2025-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Wollongong Public — Wollongong, New South Wales, Australia (enrolling)
• Cancer Research SA — Adelaide, South Australia, Australia (enrolling)
• Chinese PLA General Hospital — Beijing, Beijing Municipality, China
• Shanghai East Hospital — Shanghai, Shanghai Municipality, China
• The First Affiliated Hospital of zhejiang University School of Medicine — Hangzhou, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.